AbbVie’s Skyrizi continues to drive immunology revenue growth amid ongoing Humira erosion, with Q1 2026 global net sales reaching $4.483 billion, up 30.9% year-over-year on strong uptake across psoriasis, psoriatic arthritis, and Crohn’s indications. Sequential momentum, new label expansions, and competitive positioning versus other IL-23 and JAK inhibitors shape trader views ahead of the July 31 earnings release, when Q2 results and any updated full-year guidance will be disclosed. Analysts project sustained double-digit expansion consistent with the product’s recent trajectory and the company’s raised 2026 EPS range of $14.08–$14.28. Market-implied odds embed these fundamentals while accounting for potential variability in U.S. pricing dynamics and volume trends.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-updateWill AbbVie Q2 Global Skyrizi net revenues be above __?
Will AbbVie Q2 Global Skyrizi net revenues be above __?
BAGO
Jul 31, 2026
$18B
28%
$19B
25%
$20B
12%
$21B
45%
$22B
23%
$768 Vol.
$18B
$65 Vol.
28%
$19B
$65 Vol.
25%
$20B
$67 Vol.
12%
$21B
$0 Vol.
45%
$22B
$571 Vol.
23%
This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.AbbVie’s Skyrizi continues to drive immunology revenue growth amid ongoing Humira erosion, with Q1 2026 global net sales reaching $4.483 billion, up 30.9% year-over-year on strong uptake across psoriasis, psoriatic arthritis, and Crohn’s indications. Sequential momentum, new label expansions, and competitive positioning versus other IL-23 and JAK inhibitors shape trader views ahead of the July 31 earnings release, when Q2 results and any updated full-year guidance will be disclosed. Analysts project sustained double-digit expansion consistent with the product’s recent trajectory and the company’s raised 2026 EPS range of $14.08–$14.28. Market-implied odds embed these fundamentals while accounting for potential variability in U.S. pricing dynamics and volume trends.
This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Binuksan ang Market: Jul 18, 2026, 4:41 PM ET
Volume
$768Petsa ng Pagtatapos
Jul 31, 2026Binuksan ang Market
Jul 18, 2026, 4:41 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.AbbVie’s Skyrizi continues to drive immunology revenue growth amid ongoing Humira erosion, with Q1 2026 global net sales reaching $4.483 billion, up 30.9% year-over-year on strong uptake across psoriasis, psoriatic arthritis, and Crohn’s indications. Sequential momentum, new label expansions, and competitive positioning versus other IL-23 and JAK inhibitors shape trader views ahead of the July 31 earnings release, when Q2 results and any updated full-year guidance will be disclosed. Analysts project sustained double-digit expansion consistent with the product’s recent trajectory and the company’s raised 2026 EPS range of $14.08–$14.28. Market-implied odds embed these fundamentals while accounting for potential variability in U.S. pricing dynamics and volume trends.
This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Volume
$768Petsa ng Pagtatapos
Jul 31, 2026Binuksan ang Market
Jul 18, 2026, 4:41 PM ETResolver
0x65070BE91...AbbVie’s Skyrizi continues to drive immunology revenue growth amid ongoing Humira erosion, with Q1 2026 global net sales reaching $4.483 billion, up 30.9% year-over-year on strong uptake across psoriasis, psoriatic arthritis, and Crohn’s indications. Sequential momentum, new label expansions, and competitive positioning versus other IL-23 and JAK inhibitors shape trader views ahead of the July 31 earnings release, when Q2 results and any updated full-year guidance will be disclosed. Analysts project sustained double-digit expansion consistent with the product’s recent trajectory and the company’s raised 2026 EPS range of $14.08–$14.28. Market-implied odds embed these fundamentals while accounting for potential variability in U.S. pricing dynamics and volume trends.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update
Mag-ingat sa mga external link.
Mag-ingat sa mga external link.
Mga Madalas na Tanong